Le Lézard
Classified in: Health, Business
Subject: LIC

Clinerion partners with Eugen to expand Patient Network Explorer coverage to patients and hospitals in Uruguay


MONTEVIDEO, Uruguay, Nov. 27, 2019 /PRNewswire-PRWeb/ -- Eugen, a clinical development service provider based in Uruguay, will support Clinerion's expansion by promoting hospitals in the country to join Patient Network Explorer (PNEx), adding to the platform true global representativeness. They will use PNEx to provide clients with solid real patient health data insights when choosing their clinical trial's geographic distribution, better trial design tools and effective patient enrollment. Hospitals in Uruguay will increase their visibility and be in a better position to attract global multicentric trials while providing patients with innovative treatments.

Eugen works together with the government in Uruguay and leading local sites to increase the flow of clinical trials to Latin America in general, and Uruguay in particular, by creating an ecosystem that benefits biopharma companies and provides patients with the best clinical development programs. The country recently made headlines with its pioneer medical and recreative cannabis regulation, setting the basis for hundreds of millions of dollars in investments ? and is going a step further, having just revamped its clinical research regulation.

"In this context, our partnership with Clinerion couldn't be timelier as Uruguay has gradually shifted its economic model to transform itself into a center of innovation in Latin America," says Claudia Rodriguez Verde, Director of Operations of Eugen. "Clinerion's Patient Network Explorer is already reshaping drug development worldwide and brings to Uruguay and Latin America the new models of clinical trials that use data and artificial intelligence. We are very enthusiastic about this partnership and we are certain it will leverage Uruguay's efforts to be at the forefront of clinical research, as well as being a meaningful step to provide Eugen's customers with precise data generated in real-time."

"This partnership is true to Clinerion's aim of bringing the most modern treatments to patients around the world," says Ian Rentsch, CEO of Clinerion. "Joining the Patient Network Explorer platform, sites in Uruguay will become more visible for trial sponsors making site selection decisions. As a result, patients in Uruguay will gain access to leading-edge international trials matching their treatment needs."

About Clinerion
Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion's Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion's proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.
Clinerion website: http://www.clinerion.com
Clinerion's Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:
Le Vin Chin
Director, Head of Marketing & Communications
Clinerion Ltd
Elisabethenanlage 11, 4051 Basel, Switzerland
Tel.: +41 61 865 60 54
media@clinerion.com

About Eugen SRL
Eugen is a privately held company, headquartered in Montevideo-Uruguay, that aims to facilitate clinical trials in Latin America and reduce drug development costs by innovating procurement and vendor management through a unique business model. The company developed a high value-added set of services to ensure its clients, ranging from small biotech to large pharma, reach underserved markets and high-quality vendors while meeting their profitability goals and keeping their required level of corporate governance without the cost of a dedicated internal structure.
Eugen delivers solid financial cost modeling of drug development plans from concept to clinical development stages. It supports strategy design through geographic distribution of clinical trials and its cost impact all the way to vendor procurement and project finance management.
Eugen has developed a unique and innovative business model that together with its leadership's combined experience in clinical research and finance, guarantees the best decision: informed, opportune and financially sound.
Eugen website: http://www.eugenpro.com
Linkedin: https://linkedin.com/company/eugen

For more information, please contact:
Martiniano Sienra
Media & Community Manager
OSOM Digital
Av. De las Américas 6000, Suite 201, Montevideo, Uruguay
martiniano@osomdigital.com

 

SOURCE EUGEN


These press releases may also interest you

at 03:00
The plastic and reconstructive surgeons at The Institute for Advanced Reconstruction (IFAR) at The Plastic Surgery Center in New Jersey epitomize the notion that plastic surgery is much more than just cosmetic surgery and far more extensive than how...

at 03:00
Ervaxxtm, a biotechnology company pioneering the use of Dark Antigenstm to develop T-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines, has entered a licensing and research collaboration with a leading T-cell immunology...

at 02:05
The Healthcare Information and Management Systems Society (HIMSS) and Elsevier, the global information analytics business specializing in science and health, are proud to announce the call for submissions for the Annual HIMSS-Elsevier Digital...

at 01:05
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia...



News published on 27 november 2019 at 07:00 and distributed by: